leucovorin calcium / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 424 Diseases   807 Trials   807 Trials   14372 News 


«12...3233343536373839404142...235236»
  • ||||||||||  5-fluorouracil / Generic mfg.
    Retrospective data, Journal, Metastases:  Patients with Advanced Pancreatic Cancer Treated with Mistletoe and Hyperthermia in Addition to Palliative Chemotherapy: A Retrospective Single-Center Analysis. (Pubmed Central) -  Oct 28, 2023   
    In total, 206 consecutive patients were included in the study, whereof 142 patients (68.9%) received palliative chemotherapy (gemcitabine/nab-paclitaxel 33.8%; FOLFIRINOX 35.9%; gemcitabine 30.3%) while the remainder were treated with best supportive and integrative care...A total of 107/142 patients (86.3%) died during the observation period, whereby survival times differed significantly depending on the additional use of integrative mistletoe or hyperthermia: chemotherapy alone 8.6 months (95% CI 4.7-15.4), chemotherapy and only mistletoe therapy 11.2 months (95% CI 7.1-14.2), or a combination of chemotherapy with mistletoe and hyperthermia 18.9 months (95% CI 15.2-24.5). While the survival times observed for patients with advanced pancreatic cancer receiving chemotherapy alone are consistent with pivotal phase-III studies and German registry data, we found significantly improved survival using additional mistletoe and/or hyperthermia.
  • ||||||||||  leucovorin calcium / Generic mfg.
    Enrollment open, Trial completion date, Trial primary completion date:  Leucovorin for the Treatment of Language Impairment in Children With Autism Spectrum Disorder (clinicaltrials.gov) -  Oct 25, 2023   
    P2,  N=134, Recruiting, 
    Trial completion date: Nov 2023 --> Feb 2024 | Trial primary completion date: Nov 2023 --> Feb 2024 Active, not recruiting --> Recruiting | Trial completion date: Jul 2024 --> Jan 2025 | Trial primary completion date: Jul 2023 --> Jan 2025
  • ||||||||||  leucovorin calcium / Generic mfg.
    Trial completion date, Trial primary completion date:  Treatment of Social and Language Deficits With Leucovorin for Young Children With Autism (clinicaltrials.gov) -  Oct 25, 2023   
    P2,  N=80, Recruiting, 
    Active, not recruiting --> Recruiting | Trial completion date: Jul 2024 --> Jan 2025 | Trial primary completion date: Jul 2023 --> Jan 2025 Trial completion date: Dec 2023 --> Jan 2025 | Trial primary completion date: Dec 2023 --> Jan 2025
  • ||||||||||  monalizumab (IPH2201) / AstraZeneca, Innate, Imfinzi (durvalumab) / AstraZeneca
    Trial completion date, IO biomarker, Metastases:  A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors (clinicaltrials.gov) -  Oct 24, 2023   
    P1/2,  N=383, Active, not recruiting, 
    Trial completion date: Aug 2023 --> Aug 2024 | Trial primary completion date: Aug 2023 --> Aug 2024 Trial completion date: Jun 2023 --> Sep 2024
  • ||||||||||  Avastin (bevacizumab) / Roche
    Journal:  FOLFIRI-bevacizumab-induced acute toxic leukoencephalopathy. (Pubmed Central) -  Oct 23, 2023   
    ATL is mostly reversible, but the progression of neurologic symptoms was also reported. The diagnosis and cessation of the responsible agent are important in management.
  • ||||||||||  AB598 / Arcus Biosci
    Trial completion date, Trial primary completion date, Combination therapy, Monotherapy, Metastases:  ARC-25: Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers (clinicaltrials.gov) -  Oct 23, 2023   
    P1,  N=81, Recruiting, 
    Detection of DDR gene mutations from plasma ctDNA at baseline was associated with better survival outcomes of pati-ents with borderline resectable pancreatic ductal adenocarcinoma treated with neoadjuvant mFOLFIRINOX and may be a prognostic biomarker. Trial completion date: Nov 2025 --> Aug 2025 | Trial primary completion date: Nov 2025 --> Aug 2025
  • ||||||||||  5-fluorouracil / Generic mfg.
    Journal:  Arterial chemotherapy for hepatocellular carcinoma in China: consensus recommendations. (Pubmed Central) -  Oct 21, 2023   
    Therefore, an expert consensus conference was held on March 2023 in Guangzhou, China to review current practices regarding HAIC treatment in patients with HCC and develop widely accepted statements and recommendations. In this article, the latest evidence of HAIC was systematically summarized and the final 22 expert recommendations were proposed, which incorporate the assessment of candidates for HAIC treatment, procedural technique details, therapeutic outcomes, the HAIC-related complications and corresponding treatments, and therapeutic scheme management.
  • ||||||||||  Ampligen (rintatolimod) / AIM ImmunoTech
    Trial completion date, Trial primary completion date:  Ampligen Combined With SOC Versus SOC Alone Following First-Line Therapy in Subjects With LAPC (clinicaltrials.gov) -  Oct 19, 2023   
    P2,  N=90, Recruiting, 
    In this article, the latest evidence of HAIC was systematically summarized and the final 22 expert recommendations were proposed, which incorporate the assessment of candidates for HAIC treatment, procedural technique details, therapeutic outcomes, the HAIC-related complications and corresponding treatments, and therapeutic scheme management. Trial completion date: Jan 2027 --> Jul 2027 | Trial primary completion date: Nov 2026 --> Jun 2027
  • ||||||||||  Review, Journal:  Exosomes: Emerging Modulators of Pancreatic Cancer Drug Resistance. (Pubmed Central) -  Oct 14, 2023   
    The most used therapy is gemcitabine, alone or in combination with nanoparticle albumin-bound paclitaxel (nab-paclitaxel), and the multidrug FOLFIRINOX...This review illustrates the role of exosomes in PaC drug resistance. This manuscript first provides an overview of the pharmacological approaches used in PaC and, in the last part, focuses on the mechanisms exploited by the exosomes released by cancer cells to induce drug resistance.
  • ||||||||||  Cyramza (ramucirumab) / Eli Lilly, Avastin (bevacizumab) / Roche
    Journal, HEOR, Cost-effectiveness, Cost effectiveness, Metastases:  Clinical and cost-effectiveness analysis of mFOLOFX6 with or without a targeted drug among patients with metastatic colorectal cancer: inverse probability of treatment weighting. (Pubmed Central) -  Oct 11, 2023   
    This study investigated the cost-effectiveness and quality of life (QoL) within 1 year of receiving mFOLOFX6 with or without a targeted drug (bevacizumab or ramucirumab) as second-line treatment among patients with metastatic colorectal cancer (mCRC) following the failure of FOLFIRI + bevacizumab as first-line treatment...Addition of a targeted drug to the second-line mFOLOFX6 regimen not only improved the patients' QoL but was also more cost effective when the willingness-to-pay threshold was set at US$33,004 (the per capita gross domestic product of Taiwan). These patients should be reimbursed for these targeted agents by the National Health Insurance scheme in Taiwan.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Sequential multi-modality strategies for locally advanced betel-nuts related hypopharyngeal cancer in Taiwan (Exhibition area) -  Oct 6, 2023 - Abstract #ESMOAsia2023ESMO_Asia_905;    
    In western countries where HPV+ OPC prevalence is high, induction TPF response rate in locally advanced HNSCC is around 70%; Erbitux and TP (Argiris in JCO2008) response rate is 86%...In our previous study from unresectable stage IVA & IVB betal-nuts related HNSCC patients in ASCO2023, flexible chemotherapy backbones, such as TP/DP-HDFL(weekly docetaxel or paclitaxel with cisplatin and 24-hr high dose 5-fluorouracil/leucovorin infusion) with Biotherapy(EGFR or VEGFR-targeting)or Bio-immunotherapy had encouraging induction response with favorable toxicity to conversion surgery or definite CCRT...Aggressive induction therapy followed by mini-invasive surgery and then adjuvant CCRT with maintenance UFUR might be administered in selected patients with high induction response. Encouraging outcomes have been shown by sequential multi-modality strategies for locally advanced betel-nuts related hypopharyngeal cancer in Taiwan.